Exelon’s Debt Overview

Over the past three months, shares of Exelon Inc. (NASDAQ:EXC) rose by 4.58%. Before having a look at…

Over the past three months, shares of Exelon Inc. (NASDAQ:EXC) rose by 4.58%. Before having a look at the importance of debt, let’s look at how much debt Exelon has.

Exelon Debt

Based on Exelon’s balance sheet as of February 14, 2023, long-term debt is at $35.66 billion and current debt is at $4.39 billion, amounting to $40.05 billion in total debt. Adjusted for $407.00 million in cash-equivalents, the company’s net debt is at $39.64 billion.

Let’s define some of the terms we used in the paragraph above. Current debt is the portion of a company’s debt which is due within 1 year, while long-term debt is the portion due in more than 1 year. Cash equivalents includes cash and any liquid securities with maturity periods of 90 days or less. Total debt equals current debt plus long-term debt minus cash equivalents.

To understand the degree of financial leverage a company has, shareholders look at the debt ratio. Considering Exelon’s $95.35 billion in total assets, the debt-ratio is at 0.42. As a rule of thumb, a debt-ratio more than 1 indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. For example, a debt ratio of 25% might be higher for one industry, but normal for another.

debt_fig

Why Debt Is Important

Debt is an important factor in the capital structure of a company, and can help it attain growth. Debt usually has a relatively lower financing cost than equity, which makes it an attractive option for executives.

Interest-payment obligations can impact the cash-flow of the company. Equity owners can keep excess profit, generated from the debt capital, when companies use the debt capital for its business operations.

Looking for stocks with low debt-to-equity ratios? Check out Benzinga Pro, a market research platform which provides investors with near-instantaneous access to dozens of stock metrics – including debt-to-equity ratio. Click here to learn more.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Vaxart Announces Publication In Vaccines Of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal And Systemic Immunogenicity And Reduce Viral Shedding After SARS-CoV-2 Challenge

—  Data served as foundation for current vaccine candidate for planned Phase 2 research—  Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity

VXRT